Published on
May 26, 2022
- 21:00 GMT
Alpha Cancer Technologies Inc. Presents New Data from ACT-903 in Online Publication at the 2022 ASCO Annual Meeting
In a COLO-205 xenograft model, ACT-903 demonstrates tumor suppression, increased survival after single and multiple doses, and no signs of toxicity TORONTO, CANADA, May 26, 2022 /EINPresswire.com/ -- Alpha Cancer Technologies Inc. (ACT) a …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
